ClinicalTrials.gg
Not yet recruitingNCT07379424Updated Jan 30, 2026

A Single-arm, Phase II, Multi-center Clinical Trial of Sintilimab During the Perioperative Period in Patients With Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

A Phase 2 interventional study of Adjuvant therapy: sintilimab combined with radiotherapy in Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma, sponsored by chen chao Professor. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-30.

Sponsored by chen chao Professor · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
37
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies testing sintilimab in Squamous Cell Carcinoma of Head and Neck — 7 open to participants now, 8 under way, 2 of them phase 3. sintilimab · Squamous Cell Carcinoma of Head and Neck.

Planned enrollment
10th of 11
37 · median 51
Started
2026
with 3 others
Phase 2
9 of 11
5 open now
Registered
8th of 11
by date
Lead sponsor
1 of 11
chen chao Professor

Among the 11 studies testing sintilimab in Squamous Cell Carcinoma of Head and Neck, this one is the 10th largest by planned enrollment, is one of 4 that started in 2026, is one of 9 in phase 2, and was the 8th registered.

Squamous Cell Carcinoma of Head and Neck

2,023 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

7 of the 11 studies testing sintilimab in Squamous Cell Carcinoma of Head and Neck are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

About sintilimab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 434 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 310 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing sintilimab in Squamous Cell Carcinoma of Head and Neck, or all of them as a file.
02

Study summary

This study is a single-arm, multi-center Phase II clinical trial. As depicted in the following study design diagram, its objective is to observe and assess the efficacy and safety of sintilimab during the perioperative period in patients with resectable locally advanced head and neck squamous cell carcinoma.

Read the detailed description

The study aims to recruit patients with head and neck squamous cell carcinoma that has been histologically or cytologically confirmed. The patients should be newly diagnosed, resectable, locally advanced, and have not received any treatment for malignant tumors, as evaluated by the researchers. After signing the informed consent and being screened to meet the inclusion and exclusion criteria, the patients will first receive sintilimab in combination with standard chemotherapy (the specific drugs will be determined by the researchers). Sintilimab will be administered at a dosage of 200 mg, once every three weeks (Q3W).It is administered via intravenous infusion on the first day of each cycle. Efficacy evaluation is conducted after two cycles of treatment. For patients who show a response of complete remission (CR), partial remission (PR), stable disease (SD), or progressive disease (PD) during the efficacy evaluation, surgical resection will be performed. Following surgical resection, sintilimab combined with radiotherapy will be initiated. Sintilimab is administered every three weeks for a total of 15 cycles. Treatment will continue until disease progression, recurrence, intolerable toxicity, withdrawal of informed consent, initiation of other anti-tumor treatments, death, or other circumstances specified in the protocol that necessitate treatment discontinuation, whichever occurs first. The study employs RECIST v1.1 for imaging assessment. The baseline assessment will be conducted within 28 days prior to enrollment. Following 2 cycles of neoadjuvant therapy, a tumor imaging assessment will be performed once. After surgical resection, tumor imaging assessments will be conducted every 3 months (±7 days). If the imaging examination prior to signing the Informed Consent Form (ICF) is within 28 days before the initiation of treatment, it can be utilized as a screening period examination. For subjects who discontinue treatment for reasons other than disease recurrence or death, imaging assessments will also be carried out every 3 months during the first two years after treatment completion, and then every 6 months starting from the third year until a progression or death event occurs. The study will also delve into predictive efficacy biomarkers. For subjects who have signed the informed consent for biomarker sample collection, biomarker blood samples and tumor samples will be collected during the baseline period and throughout the trial. This includes possible tumor biopsies during the baseline period.

03

Conditions studied

  • Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

Keywords

  • HNSCC
  • Resectable local advanced HNSCC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

1. Written was obtained before any trial-related procedures were performed; 2. Male or female ≥18 years old; 3. Patients with locally advanced squamous cell carcinoma of the head and neck, including oral, oropharyngeal, hypopharyngeal, and laryngeal cancers (except nasopharyngeal and paranasal sinus cancers), confirmed histologically or cytologically by investigator assessment as resectable, including oral, oropharyngeal, hypopharyngeal, and laryngeal cancers; 4. Enrollment stage: stage III-IVA (AJCC 8th); 5. Operable and willing to accept radical surgery after evaluation by multidisciplinary team; 6. The patient had not received any anti-tumor treatment, including but not limited to surgery, radiotherapy, chemotherapy, immunotherapy, targeted therapy, etc.

7. At least one radiographic according to (RECIST, version 1.1); 8. PS score of 0-1; 9. Expected survival time > 3 months; 10. Adequate organ function, subject must meet the following laboratory indicators:

  1. (ANC) ≥1.5x109/L without using granulocyte colony-stimulating factor for the past 14 days.
  2. count ≥100×109/L without blood transfusion in the past 14 days.
  3. \&gt in the absence of blood transfusion or erythropoietin use in the last 14 days; 9g/dL;
  4. Total ≤1.5× value (ULN);
  5. (AST) and alanine aminotransferase (ALT) ≤2.5×ULN
  6. serum creatinine ≤1.5×ULN and (calculated by Cockcroft-Gault formula) ≥60 ml/min;
  7. good coagulation function, defined as or PT ≤1.5 times ULN;
  8. Euthyroid, defined as thyroid stimulating hormone (TSH) within the normal range. If the baseline TSH was beyond the normal range, the subjects could be included if the total T3 (or FT3) and FT4 were within the normal range.
  9. Myocardial enzymes within the normal range (simple laboratory abnormalities that were judged by the investigators as not were also allowed); 11. For women of childbearing age, a negative urine or serum pregnancy test should be performed within 3 days before receiving the first dose of study drug (day 1 of cycle 1). If a urine pregnancy test result could not be confirmed as negative, a blood pregnancy test was requested. Women who were not of reproductive age were defined as those who had been for at least 1 year or had undergone surgical sterilization or hysterectomy.

12. If there was a risk of pregnancy, all subjects (male or female) were required to use with an annual failure rate of less than 1% throughout the treatment period until 120 days after the last dose of study drug on treatment (or 180 days after the last dose of chemotherapy drug).

Exclusion criteria

Exclusion Criteria:

  1. Nasopharyngeal or paranasal sinus cancer;
  2. Distant confirmed by clinical or imaging examination;
  3. Malignant diseases other than head and neck squamous cell carcinoma (excluding radical basal cell carcinoma, skin squamous cell carcinoma, and/or radical resection carcinoma in situ) diagnosed within 3 years before the first dose;
  4. Currently participating in an interventional clinical study treatment, or receiving another study drug or using a study device within 4 weeks before the first dose;
  5. Previous therapy with an , anti-PD-L1, or anti-PD-L2 agent or an agent targeting another T-cell receptor that stimulates or coinhibits it (e.g., CTLA-4, OX-40, CD137);
  6. Received anti-tumor Chinese patent medicine or immunomodulatory drugs (including thymosin, interferon and interleukin, except for local use to control pleural effusion) with systemic treatment within 2 weeks before the first dose;
  7. Active disease requiring systemic therapy (e.g., disease-modifying agents, , or agents) occurred within 2 years before the first dose. Alternative therapies (e.g., thyroxine, insulin, or physiological glucocorticoids for adrenal or pituitary insufficiency) were not considered systemic therapy;
  8. Receiving systemic glucocorticoids (excluding topical glucocorticoids by nasal spray, inhalation, or other route) or any other form of immunosuppressive therapy within 7 days before the first study dose; Note: Physiologic doses of glucocorticoids (prednisone ≤10mg/ day or equivalent) were allowed.
  9. Known allogeneic organ transplantation (except corneal transplantation) or hematopoietic stem cell transplantation;
  10. Known to be allergic to sintilimab or ;
  11. Known history of (HIV) infection (i.e., HIV1/2 antibody positive);
  12. Untreated active (defined as both HBsAg positivity and HBV-DNA copies greater than the in the laboratory of the participating center);

    Note: Subjects with hepatitis B who met the following criteria were also eligible for inclusion:

    1. HBV viral load \&lt before the first dose; 1000 copies /ml (200IU/ml), subjects should receive anti-HBV therapy throughout the study chemotherapy to avoid viral reactivation
    2. Subjects with anti-HBc (+), HBsAg (-), anti-hbs (-), and HBV viral load (-) do not require prophylactic anti-HBV therapy, but close monitoring for viral reactivation is required
  13. Active -infected subjects (HCV-antibody positive with an HCV-RNA level above the lower limit of detection);
  14. Have received a within 30 days before the first dose (cycle 1, day 1); Note: Administration of injectable inactivated virus vaccine against seasonal influenza within 30 days before the first dose is allowed; Live, attenuated, intranasal influenza vaccine was not allowed.
  15. Pregnant or lactating women;
  16. The presence of any serious or uncontrolled systemic illness, such as:

    1. significant rhythm, conduction or morphological abnormalities on resting that are symptomatic and difficult to control, such as complete left bundle branch block, ≥ Ⅱ degree heart block, ventricular arrhythmia or atrial fibrillation;
    2. unstable angina, congestive heart failure, (NYHA) class ≥2 chronic heart failure;
    3. any arterial thrombosis, embolism, or ischemia, such as myocardial infarction, unstable angina, cerebrovascular accident, or , etc. within 6 months before enrollment;
    4. poor blood pressure control (systolic blood pressure > 140mmHg, diastolic blood pressure > 90mmHg);
    5. a history of noninfectious pneumonia requiring glucocorticoid therapy within 1 year before the first dose or current clinically active interstitial lung disease;
    6. active pulmonary tuberculosis;
    7. presence of active or uncontrolled infection requiring systemic therapy;
    8. clinically active diverticulitis, abdominal abscess, and gastrointestinal obstruction;
    9. liver diseases such as cirrhosis, decompensated liver disease, acute or chronic active hepatitis;
    10. poorly controlled diabetes (fasting blood glucose (FBG) > 10mmol/L);
    11. urine routine showed urinary protein ≥++ and confirmed 24-hour urinary protein quantitation > 1.0g;
    12. patients with mental disorders who are unable to cooperate with treatment;
  17. Medical history or evidence of disease, treatment or laboratory abnormalities, or other conditions deemed by the investigator to be inappropriate for enrollment that may interfere with the results of the trial or preclude full participation in the study.
Terms in these criteria, in plain language(29)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
37 participants (estimated)

Study arms

  • Experimental
    Chemotherapy + PD-1 inhibitor

    Neoadjuvant therapy: PD-1 inhibitor combined with chemotherapy Sintilimab: * Specification: 100 mg/10 ml * Administration method: 200 mg IV infusion, Q3W, 2 cycles; Standard chemotherapy: paclitaxel (albumin-bound) 260mg/m2 d1+ cisplatin 80mg/m2 d1 or paclitaxel (albumin-bound) 260mg/m2 d1+ nedaplatin 80mg/m2 d1.

    Combination Product: Adjuvant therapy: sintilimab combined with radiotherapy

Interventions

  • Combination productAdjuvant therapy: sintilimab combined with radiotherapy

    Drug page: SintilimabStudies of SintilimabSintilimab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The efficacy was assessed following 2 cycles of neoadjuvant therapy. Patients with efficacy evaluated as CR/PR/SD/PD underwent surgical resection. After surgical resection, sintilimab combined with radiotherapy was initiated as adjuvant therapy, and sintilimab was administered at a dosing interval of Q3W for 15 cycles.

06

What researchers measure

Primary outcomes

  1. 1-year DFS rate

    Investigator-assessed relapse-free survival at 1 year according to RECIST v1.1

    Time frame: 1 year

Secondary outcomes

  1. ORR

    The objective response rate was assessed according to RECIST 1.1 criteria

    Time frame: Six weeks after enrollment

  2. DCR

    Disease control rate based on RECIST 1.1 criteria

    Time frame: Six weeks after enrollment

  3. pCR

    Refers to the proportion of patients with no residual tumor in the primary tumor and lymph nodes resected

    Time frame: Six weeks after enrollment

  4. MPR

    Refers to the proportion of patients with ≤10% viable tumor cells in the postoperative resection specimen

    Time frame: Six weeks after enrollment

  5. OS

    Overall survival

    Time frame: Occurrence or end of follow-up(3 years after enrollment), which comes first

  6. AE

    The severity of adverse events was graded during the study and during follow-up according to the NCI CTCAE, version 5.0

    Time frame: through study completion, an average of 1 year

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — Privacy

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2026; primary completion for Aug 2027, 18 months later.

Of 299 non-industry phase 2 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 85. This study's planned 18 months is below that.

Counting every sponsor, half of 366 studies reached it within 53 months; a quarter within 35 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 4, 2025
First posted
Jan 30, 2026
StartEst.
Jan 28, 2026
Primary completionEst.
Aug 25, 2027
CompletionEst.
Aug 25, 2028
Last update
Jan 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07379424
Lead sponsor
chen chao Professor
Responsible party
chen chao Professor (Professor of Clinical, Zhejiang Cancer Hospital) — Sponsor-investigator
First posted
Jan 30, 2026
Start date
Jan 28, 2026 (estimated)
Primary completion
Aug 25, 2027 (estimated)
Completion
Aug 25, 2028 (estimated)
Last update
Jan 30, 2026

Study contacts

Ting Jin, M.D
Contact
jinting22222@163.com
15968837040

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sintilimab

Start the discussion